1d – Crosswalk for Alternate Second Drug Management Program Notice

2018 (old version)

2021 (new version)

Type of
Change
Rev

Not applicable

Insert heading: “YOUR ACCESS TO CERTAIN
PART D DRUGS WILL NOT BE LIMITED”

For More Information
and Help with This
Notice
For More Information
and Help with This
Notice

Include placeholders for plans to insert mailing
address, email address, and/or other methods of
contact
Clarify that email address and/or other methods of
contact are optional by adding “If the plan has a
dedicated line (toll free), staff person, web portal,
etc. for its DMP, that information may be included
in this section, as applicable.”

Rev

For More Information
and Help with This
Notice

Do not include signature for letter including name
and credential of clinical staff

Rev

Rev

Reason for change
Commenter
recommendation
during 60-day
comment period to
maintain consistency
with first and second
notices that have a
prominent heading to
attract enrollee
attention and provide
context for notice
Completeness

Burden
Change
No

No

Commenter
No
recommendation
during 60-day
comment period since
not all plans utilize
email or alternate
contact methods and
to minimize new
variable fields that
may delay
programming ahead
of required
implementation date
Commenter
No
recommendation
during 60-day

comment period to
protect privacy of
clinical staff
INFORMATION NOT RELEASABLE TO THE PUBLIC UNLESS AUTHORIZED BY LAW: This pre-decisional,
privileged, and confidential information is for internal government use only, and must not be disseminated, distributed, or
copied to persons not authorized to receive the information. For Preliminary discussion only, pending review of all public
comments. Unauthorized disclosure may result in prosecution to the full extent of the law.